Pooled RNA: extraction free testing of saliva for SARS-CoV-2 detection

- 2 Orchid M. Allicock^{1*}, Devyn Yolda-Carr^{1*}, John A. Todd², Anne L. Wyllie^{1#}
- ¹Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT 06510,
- 4 USA;

6

9

11

12

13

14

15

16

17

18

19

20

21

22

1

- ⁵ Flambeau Diagnostics, Madison WI 53719, USA.
- 7 *These authors contributed equally to this article
- 8 *Correspondence: anne.wyllie@yale.edu
- 10 Keywords: SARS-CoV-2; pooling; real-time RT-PCR; surveillance testing

Abstract

The key to limiting SARS-CoV-2 spread is to identify virus-infected individuals (both symptomatic and asymptomatic) and isolate them from the general population. Hence, routine weekly testing for SARS-CoV-2 in all asymptomatic (capturing both infected and non-infected) individuals is considered critical in situations where a large number of individuals congregate such as schools, prisons, aged care facilities and industrial workplaces. Such testing is hampered by operational issues such as cost, test availability, access to healthcare workers and throughput. We developed the SalivaDirect RT-qPCR assay to increase access to SARS-CoV-2 testing via a low-cost, streamlined protocol using self-collected saliva. To expand the single sample testing protocol, we explored multiple extraction-free pooled saliva testing workflows prior to testing with the

SalivaDirect assay. A pool size of five, with or without heat inactivation at 65°C for 15 minutes prior to testing resulted in a positive agreement of 98% and 89%, respectively, and an increased Ct value shift of 1.37 and 1.99 as compared to individual testing of the positive clinical saliva specimens. Applying this shift in Ct value to 316 individual, sequentially collected, SARS-CoV-2 positive saliva specimen results reported from six clinical laboratories using the original SalivaDirect assay, 100% of the samples would have been detected (Ct value >45) had they been tested in the 1:5 pool strategy. The availability of multiple pooled testing workflows for laboratories can increase test turnaround time, permitting results in a more actionable time frame while minimizing testing costs and changes to laboratory operational flow.

Introduction

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

During the emergence and spread of the SARS-CoV-2 virus in 2020, the majority of testing for the virus was aimed at diagnosing COVID-19 (the disease that it causes) in patients presenting with symptoms characteristic of COVID-19. An infected person may develop COVID-19 disease symptoms 3 to 8 days post infection or may never develop symptoms (asymptomatic) (1-3). However, asymptomatic individuals can be infectious, carrying viral loads high enough to spread the virus to uninfected individuals. Soon thereafter it became clear that to control the spread of SARS-CoV-2 infection, a twopronged approach must be used in the general population to prevent viral spread from infected asymptomatic individuals to the non-infected population. The first prong involves utilisation of physical barriers (e.g. face masks) to minimize virus spread via aerosols (4, 5). The second prong involves routine weekly testing for SARS-CoV-2 in all asymptomatic (capturing both infected and non-infected) individuals at highrisk for infection (6, 7). Such testing is considered critical in situations where many individuals congregate such as schools, prisons, aged care facilities and industrial workplaces. Testing strategies rely on obtaining a respiratory tract specimen and an assay for the presence of SARS-CoV-2 antigen or genome. It is generally considered that molecular tests for viral genome are more sensitive than the antigen tests; however, they can be costly, can take days to return results and can be hard to scale for large population testing. Furthermore, for tests requiring a swab-based respiratory tract specimen, these can be uncomfortable and difficult to obtain, especially under weekly self-collected specimen protocols, deterring individuals from participating in testing (8). Early in the pandemic response, saliva emerged as an alternative specimen for SARS-CoV-2 testing and by 2021 it became apparent that a self-collected specimen could obviate the disadvantages of respiratory tract swab specimens. Importantly, the clinical sensitivities for SARS-CoV-2 detection were similar between respiratory tract swab and saliva specimens(9).

To address some of the limitations of testing, SalivaDirectTM was developed as an open-source protocol wherein clinical laboratories could adopt a streamlined, easy-to-use, inexpensive, scalable and flexible genomic (RT-qPCR) assay method for SARS-CoV-2 detection (10). Importantly the assay is based upon a simple self or observed saliva collection protocol. The SalivaDirectTM assay was developed to simplify testing individual saliva specimens; however, with the momentum around testing large-scale asymptomatic populations (e.g. school students, faculty and staff) where SARS-CoV-2 prevalence is low, in a cost-effective manner, a more scalable protocol is required for sustainable testing programs. We therefore investigated higher throughput protocols, wherein saliva specimens are pooled prior to testing with RT-qPCR. These pooled testing approaches were evaluated for the clinical sensitivity of SARS-CoV-2 detection.

Methods

Ethics statement

The use of de-identified saliva specimens from healthy or asymptomatic individuals was approved by the Institutional Review Board of the Yale Human Research Protection Program (Protocol ID. 2000028394) (11). Study participants were informed in writing about the purpose and procedure of the study, and consented to study participation through the act of providing the saliva sample; the requirement for written informed consent was waived by the Institutional Review Board. Additionally, the Institutional Review Board of the Yale Human Research Protection Program determined that the use of de-identified, remnant COVID-19-positive clinical samples obtained from laboratory partners for the RT-qPCR testing conducted in this study is not research involving human subjects (Protocol ID: 2000028599).

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

Sample Collection All de-identified saliva samples used in the current study were collected unsupplemented into simple laboratory plastic tubes per the SalivaDirect protocol (12). All samples were tested with the SalivaDirect assay(13) in our research laboratory to confirm SARS-CoV-2 status. Samples were stored at -80°C until further analysis. Pooled Sample Testing To understand the effect of sample dilution by pooling, on clinical sensitivity, a total of 20 saliva specimens which previously tested positive with the modified CDC assay RT-qPCR assay, with resulting cycle threshold (Ct) values between 22.98 and 39.43, were diluted 1:5, 1:10, and 1:20 with negative saliva specimens from healthcare workers(14). Undiluted specimens and pools were tested with the standard SalivaDirect RT-qPCR assay. After identifying the optimal pool size, we performed an initial workflow evaluation using 5 different pooled samples, each composed of a single SARS-CoV-2-positive saliva sample pooled with 4 SARS-CoV-2-negative saliva samples, in a 1:5 dilution. To confirm our initial workflow findings and assess the sensitivity of viral detection when pooling, 20 additional pools (1 positive with 4 negative saliva specimens) were prepared and tested using the five different workflows. The five different saliva pooling workflows investigated in both the initial and confirmation studies are depicted in Figure 1. All saliva samples were thawed on ice prior to testing and all samples were tested in duplicate. For workflows A and C (Figure 1a), 50 µl of each sample, (including the SARS-CoV-2-positive saliva) were pooled to 250 µL total volume, followed by vigorous vortexing. For workflow A, 50 µl of the pooled sample was tested following the standard SalivaDirect protocol(10). For workflow C the remaining

sample was treated with 10 µl of proteinase K then heat inactivated before testing directly without further treatment in the SalivaDirect RT-qPCR assay. Workflows B, D and E (**Figure 1b**) involved incubating individual non-pooled samples at 65°C for 15 minutes before combining 50 µl of each sample into pools of 5 pre-treated samples. For workflow B, 50 µl of the pool of pre-treated samples was tested through the standard SalivaDirect protocol. For workflow E, 10 µl of each of these pre-treated pools was removed and tested with the SalivaDirect RT-qPCR assay without proteinase K treatment. Finally, for workflow D, 10 µl of proteinase K was added to the remaining volume of the pre-treated pool then heat inactivated before testing in the SalivaDirect RT-qPCR assay.

Assessment of clinical Ct values with pooling

To evaluate the real-world potential loss of sensitivity on clinical samples with pooling, we estimated the average change in Ct value for each pooled testing workflow using the results from the 25-sample workflow confirmation study. We then estimated how the change in Ct value would potentially impact assay sensitivity by applying the ΔCt value (with pooling) to real world SalivaDirect RT-qPCR SARS-CoV-2 testing results. Six SARS-CoV-2 testing sites around the U.S., all testing with the standard SalivaDirectTM protocol, provided sequential testing results (Ct values for positive specimens) during August 2021 and to these values we applied the ΔCt value that we estimated.

Statistical analyses

The correlation of Ct values between each workflow and the individual positive samples was assessed using the Pearson correlation coefficient and represented graphically with linear regression. The negative RT-PCR of the target gene was set at the Ct value of 45 for the statistical analysis. All statistical analyses were performed using GraphPad Prism

version 9 (GraphPad Software, San Diego, CA). For the calculation of percent positive agreement, samples are considered positive at Ct < 45.

Results

Pooling sizes and workflow selection

We initially performed a limit of detection range-finding study to determine the impact of sample dilution via pooling with the SalivaDirect RT-qPCR assay on detection sensitivities. As pool size increased the resulting assay Ct values increased as well, generally in a linear manner. The smallest change in Ct values (i.e. loss of assay sensitivity) of pooled versus neat saliva was obtained with 1:5 pooling (1 positive and 4 negative saliva samples). Thus a 1:5 pooling strategy was employed for workflow analysis. Our preliminary results indicated that the SalivaDirect assay was able to detect SARS-CoV-2 in pooled saliva specimens with high virus loads, but additional testing was required to optimize saliva pooling and processing workflows.

Table 1. Distribution of the Ct values of clinical saliva samples used for pooling.

Ct range*	No. samples Workflow A (n=22)	No. samples Workflow B - E (n=25)
20.0-29.9	7 (32%)	7 (28%)
30.0-34.9	5 (23%)	8 (32%)
35.0-40.0**	10 (45%)	10 (40%)

^{*}samples <40 Ct are considered positive for SARS-CoV-2

**mean Ct for the CFX96 Touch RT-qPCR instrument when determining LOD for analytical sensitivity using this set of reagents was 36.7

Extrapolating from previous work (Watkins et al. 2021), we selected 5 workflows representing different pooling strategies. Initial analyses using 5 pools showed that 4 workflows (A-D) provided similar results for most of the pools (see **Table S1**). Workflow E provided a much larger shift in Ct values for all five pools (5.26) and hence loss of assay sensitivity. As expected, a shift in Ct values (to higher) was noted for all five pooled workflows compared the standard SalivaDirect RT-qPCR assay performed on the undiluted positive sample. For workflows A-E, initial analysis of the differences in Ct values between the pools and individual positive samples resulted in a Ct shift of 2.17 to 3.50. Workflow E was omitted from further evaluations.

Workflow analysis

148

149

150

151

152

153

154

155

156

157

158 Twenty-five SARS-CoV-2 saliva specimens were used for pooling, with each pool 159 including one unique positive specimen and 4 negative specimens, to make 25 contrived 160 pools. The Ct values (obtained at the site of saliva collection) for SARS-CoV-2-positive 161 samples ranged from 22.98 to 39.43. The majority (40 to 45%) of the specimens had Ct 162 values >35 indicating a relatively low concentration of virus, 28 to 32% of the specimens 163 had Ct values <30 indicating a higher concentration of virus (**Table 1, Table S2**). 164 We assessed the sensitivity of each workflow by comparing to see which workflow had 165 the smallest shift in Ct values between the undiluted sample processed with SalivaDirect 166 RT-qPCR assay and the workflow in question, and by comparing which workflow had 167 the smallest number of pools dropping below the sensitivity threshold (between Ct 40 to 168 45). When compared to undiluted samples processed with the standard SalivaDirect 169 assay, Workflows A and B provided the highest sensitivity (Figure 2). Workflows A and 170 B resulted in 3 and 1 pool(s) with Ct increases to 40 and 45, respectively. In contrast, 171 workflows C and D demonstrated the lowest in clinical sensitivity, with loss in detection 172 in 8/25 and 10/25 pools processed by these workflows respectively.

Workflow A resulted in a positive agreement of 88.6% (86.4% and 91.0% for the individual replicates), compared to the individual testing results using the standard SalivaDirect protocol. Workflow B resulted in a 98% positive agreement (100% and 96% for the replicates), compared to the individual testing results using the standard SalivaDirect protocol (**Figure 2a**). The positive agreement for workflows C and D were less, with averages of 76% and 62%, respectively.

A theoretical Ct shift of Log₂(n) can be estimated for most RT-qPCR tests due to the dilution of positive samples when pooled with negative samples. This means that for pools of 5, a Ct value shift of 2.3 would be expected. The Ct shift observed for Workflows A and B were below this expected value, with Ct value shift of 1.99 and 1.37 respectively, confirming a slight loss of assay sensitivity. Workflows C demonstrated the

Impact of pooling on clinical sensitivity

worst Ct value shift of 2.81.

To determine the pragmatic loss of clinical sensitivity with pooling before performing the SalivaDirect RT-qPCR assay with workflows A-D, we queried six SalivaDirect CLIA laboratories across the United States for the Ct values obtained from sequential testing of saliva samples for SARS-CoV-2. These values and the breakdown of samples per site are presented in **Figure 3** (raw data available in **Table S3**). The average Ct value for the six labs was 28.0. There was no statistical difference in Ct values across the labs. Out of a total of 613 determinations across the labs, only 16 samples (2.6%) had Ct values between 38-40. Considering the calculated (from the confirmation study) worst case Ct shift in pooling workflows A and B of 1.99, and if all of the 613 determinations had been made using workflow A or B, these 16 samples would have shifted Ct to between 40 and 42. While considered negative using the individual testing workflow, these 2.6% of samples would fall into a grey zone of 40-45 Ct values.

Discussion

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

Widespread surveillance of asymptomatic individuals is one of the main methods of controlling the spread of SARS-CoV-2. The pooling of samples before testing is a resource-saving approach to increase testing capacity, especially for surveillance in a population with a low infection rate (14), such as travellers, school populations and employees of large organisations. Additionally, testing these members of the community serve as a proxy to the broader community, perhaps identifying larger outbreaks through family members and their associated activities. As saliva is easy to collect from a large number of people, pooling strategies are thus a natural extension to surveillance programs. While pooling saliva does impact assay sensitivity and potentially decrease virus detection, the actual impact appears to be minimal. In the current study, we demonstrated that weakly positive samples (Ct values of 38 to 40) may be missed when testing pools of larger sizes (pools > 5) when compared to testing samples individually. However, on the basis of the calculated relative sensitivity loss resulting from pooling, we looked at six datasets comprising 613 SARS-CoV-2 positive samples from across the U.S. Using such real world data we found that pooling saliva in groups of 5 samples prior to testing is expected to have minimal impact on clinical sensitivity. Based upon the lab reported Ct values only 2.6% of these samples would have shifted into a Ct 40-45 grey zone using the proposed SalivaDirect pooling workflows A or B. Importantly, if these samples were pooled, none would have become undetectable. It is advised that any sample pool resulting in Ct values between 40-45 should be retested individually using the standard SalivaDirect protocol. Surveillance programs for SARS-CoV-2 genomic testing in low prevalence populations must be operationally pragmatic. First, they need to be cost-effective. Pooled testing significantly reduces reagent costs, lab personnel cost, and lab resource needs. Second,

these programs need to be easy to implement. Self-collection of a simple saliva specimen obviates the need for healthcare workers to collect specimens and the associated personal protective equipment. Third, programs should utilize existing resources for sample collection. Self-collection of saliva can be performed anywhere and the resulting specimen can be deposited at a drop site location (e.g. school or workplace entrance) such that specimens from thousands of participants are collected in a parallel manner. Pooling of specimens once received in the laboratory for testing should fit into established laboratory accessioning and pre-analytic workflows. Finally, the end test results must provide acceptable clinical sensitivities and specificities. We have shown that a salivabased RNA-extraction-free pooled (1:5) testing strategy results in detection of 97.4-100% SARS-CoV-2-positive samples, as compared to individual testing. Large pooled testing programs have already demonstrated the efficacy of pooled saliva testing for helping to keep schools safely open (15, 16), with pooled samples having a similar sensitivity to the molecular testing of individual samples, in terms of both qualitative and quantitative (comparable Ct values between pooled and individual samples) measures.

Throughout the pandemic, clinical laboratories have been hesitant to implement pooled sample testing (17) due to: 1) stringent workflows which do not fit within existing laboratory operations, 2) a lack of clear guidance on how to implement such methods and 3) the perception that clinical sensitivity of the assay will be lost with pooling. The methods we propose in the current study demonstrate minimal impact on assay sensitivity with 5 samples per pool, and are straightforward extensions of a simple SARS-CoV-2 testing method which can be easily conducted manually, without requiring additional investment. SalivaDirect is a flexible extraction-free platform for RT-qPCR testing. For ease of implementation and safety of lab personnel, multiple workflows (18) were developed for

the testing of individual samples. We sought to extend this level of flexibility for labs seeking to offer pooled testing. We demonstrated that workflows A and B provide the best assay sensitivity, with B providing a heat pre-treatment step for labs who require it by local Environmental Health and Safety guidelines. Consequently, workflows A and B were selected as the proposed approaches for pooling of the SalivaDirect test.

Overall, surveillance testing is not generally easy, requiring a pivot by traditionally clinical diagnostic labs, especially when scalable protocols do not exist. Thus, when a decrease in positive cases are observed, there is a psychological and practical desire to decrease testing. However, these dips in COVID-19 cases can lead to a decrease in pandemic preventative measures, which inevitably leads to disease resurgence. Additionally, with the introduction of different variants of concern, the need for affordable and sustainable mass testing strategies only becomes more urgent. Our findings suggest that combining saliva with a practical pooling protocol will enable easier SARS-CoV-2 surveillance testing, especially in resource-limited settings. Such pooled testing has the potential to significantly reduce the overall number of tests and associated costs. This would in turn operationally permit an increased frequency of testing, meaning an increased likelihood of detecting individuals earlier in their infection. This approach should allow broader screening in schools and workplaces for SARS-CoV-2 testing and importantly lay the foundation for managing future upper respiratory infection mediated pandemics.

Data Availability

Data from this study is available in the supplemental information.

Author contributions

272 A.L.W. conceived the study and developed the study protocol. D.A.Y-C. executed the

study. A.L.W. co-ordinated external laboratory data. O.M.A. and A.L.W. analyzed the data.

O.M.A. assisted with the design of the statistical analysis. J.A.T., D.A.Y-C, O.M.A., and

A.L.W. wrote and edited the manuscript.

Acknowledgements

We thank our external laboratory partners for their time and cooperation to make this

valuable extension of the SalivaDirect assay possible for other laboratories around the

country. This work was funded by Flambeau Dx (A.L.W) and Fast Grant from Emergent

Ventures at the Mercatus Center at George Mason University (A.L.W).

Figures

Figure 1. The SalivaDirectTM pooled testing workflows evaluated in the study. (A) For workflows A (purple) and C (gold), 50 μl of SARS-CoV-2-positive saliva and 200 μL total volume of four SARS-CoV-2-negative saliva samples (50 μl each) were pooled and vigorously vortexed to mix. For workflow A, 50 μl of the pooled sample was tested following the standard SalivaDirect protocol. For workflow C the remaining sample was treated with 10 μl of proteinase K then heat inactivated before testing directly without further treatment in the SalivaDirectTM RT-qPCR assay. (B) For workflows B, D and E, individual, non-pooled samples were incubated at 65°C for 15 minutes before combining 50 μl of each sample into pools of 5 pre-treated samples. For workflow B (pink), 50 μl of the pool of pretreated samples was tested through the standard SalivaDirect protocol. For workflow E (orange), 10 μl of each of these pre-treated pools was removed and tested

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

above the location of the laboratory.

with the SalivaDirectTM RT-qPCR assay without proteinase K treatment. Finally, for workflow D (blue), 10 µl of proteinase K was added to the remaining volume of the pretreated pool then heat inactivated before testing in the SalivaDirect[™] RT-gPCR assay. Figure 2. SARS-CoV-2 N1 gene detection with individual saliva-based RNAextraction-free RT-qPCR testing versus pooled sample testing using Workflows A-D. A) N1 detection of one positive sample pooled and tested with equal volumes of 4 negative samples correlated to the Ct value obtained when samples were tested individually. B). Ct values obtained from each sample tested individually and when combined with 4 negative samples and tested with each of the workflows. The N1 Ct cutoff for classifying individual samples as positive is 40 (as indicated by the grey area under the horizontal dashed line. No cutoff was set for the pooled samples. B) line - median values Figure 3 Detection of SARS-CoV-2 N1 gene persists when Ct value shift from workflows A is applied to data from six clinical laboratories across the US in July 2021. Each dot represents the clinical samples. The black line indicates the median value of the samples, and the number of samples processed at each site in square brackets

References

314

- 315 1. Wells PM, Doores KJ, Couvreur S, Nunez RM, Seow J, Graham C, Acors S,
- Kouphou N, Neil SJD, Tedder RS, Matos PM, Poulton K, Lista MJ, Dickenson RE,
- 317 Sertkaya H, Maguire TJA, Scourfield EJ, Bowyer RCE, Hart D, O'Byrne A, Steel
- KJA, Hemmings O, Rosadas C, McClure MO, Capedevilla-Pujol J, Wolf J, Ourselin
- 319 S, Brown MA, Malim MH, Spector T, Steves CJ. 2020. Estimates of the rate of
- 320 infection and asymptomatic COVID-19 disease in a population sample from SE
- 321 England. J Infect 81:931-936.
- 322 2. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, Wang M. 2020. Presumed
- Asymptomatic Carrier Transmission of COVID-19. JAMA 323:1406-1407.
- 324 3. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. 2020. Substantial
- 325 undocumented infection facilitates the rapid dissemination of novel coronavirus
- 326 (SARS-CoV-2). Science 368:489-493.
- 327 4. Asadi S, Cappa CD, Barreda S, Wexler AS, Bouvier NM, Ristenpart WD. 2020.
- 328 Efficacy of masks and face coverings in controlling outward aerosol particle
- emission from expiratory activities. Sci Rep 10:15665.
- 330 5. Leung NHL, Chu DKW, Shiu EYC, Chan K-H, McDevitt JJ, Hau BJP, Yen H-L, Li Y,
- 331 Ip DKM, Peiris JSM, Seto W-H, Leung GM, Milton DK, Cowling BJ. 2020.
- Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med
- 333 26:676-680.
- 334 6. Hellewell J, Russell TW, Investigators S, Field Study T, Crick C-C, group CC-w,
- Beale R, Kelly G, Houlihan C, Nastouli E, Kucharski AJ. 2021. Estimating the

- 336 effectiveness of routine asymptomatic PCR testing at different frequencies for the
- detection of SARS-CoV-2 infections. BMC Med 19:106.
- 338 7. Paltiel AD, Zheng A, Walensky RP. 2020. Assessment of SARS-CoV-2 Screening
- 339 Strategies to Permit the Safe Reopening of College Campuses in the United States.
- 340 JAMA Netw Open 3:e2016818.
- 341 8. Nacher M, Mergeay-Fabre M, Blanchet D, Benois O, Pozl T, Mesphoule P, Sainte-
- Rose V, Vialette V, Toulet B, Moua A, Saout M, Simon S, Guidarelli M, Galindo M,
- Biche B, Faurous W, Chaizemartin L, Fahrasmane A, Rochemont D, Diop F, Niang
- M, Pujo J, Vignier N, Dotou D, Vabret A, Demar M. 2021. Diagnostic accuracy and
- 345 acceptability of molecular diagnosis of COVID-19 on saliva samples relative to
- 346 nasopharyngeal swabs in tropical hospital and extra-hospital contexts: The
- 347 COVISAL study. PLoS One 16:e0257169.
- 348 9. Tan SH, Allicock O, Armstrong-Hough M, Wyllie AL. 2021. Saliva as a gold-
- 349 standard sample for SARS-CoV-2 detection. Lancet Respir Med
- 350 doi:10.1016/s2213-2600(21)00178-8.
- 351 10. Vogels CBF, Watkins AE, Harden CA, Brackney DE, Shafer J, Wang J, Caraballo
- C, Kalinich CC, Ott IM, Fauver JR, Kudo E, Lu P, Venkataraman A, Tokuyama M,
- 353 Moore AJ, Muenker MC, Casanovas-Massana A, Fournier J, Bermejo S, Campbell
- 354 M, Datta R, Nelson A, Yale IRT, Dela Cruz CS, Ko AI, Iwasaki A, Krumholz HM,
- 355 Matheus JD, Hui P, Liu C, Farhadian SF, Sikka R, Wyllie AL, Grubaugh ND. 2021.
- 356 SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing
- 357 capacity. Med (N Y) 2:263-280.e6.
- 358 11. Allicock OM, Petrone ME, Yolda-Carr D, Breban M, Walsh H, Watkins AE,
- Rothman JE, Farhadian SF, Grubaugh ND, Wyllie AL. 2021. Usability of saliva

- 360 collection devices for SARS-CoV-2 diagnostics. medRxiv doi:10.1101/2021.02.01.21250946.
- FDA. 2020. SalivaDirect EUA Summary. https://www.fda.gov/media/141192/.
 Accessed 12/21/2021.
- 364 13. Vogels C, Orchid M, E D, Chaney C, Isabel M, Grubaugh N, Anne L.

 365 SalivaDirect™: RNA extraction-free SARS-CoV-2 diagnostics v6

 (protocols.io.btdnni5e). protocolsio doi:10.17504/protocols.io.btdnni5e.
- Watkins AE, Fenichel EP, Weinberger DM, Vogels CBF, Brackney DE, Casanovas Massana A, Campbell M, Fournier J, Bermejo S, Datta R, Dela Cruz CS, Farhadian
 SF, Iwasaki A, Ko AI, Grubaugh ND, Wyllie AL. 2021. Increased SARS-CoV-2
 Testing Capacity with Pooled Saliva Samples. Emerg Infect Dis 27:2-5.
- 371 15. Mendoza RP, Bi C, Cheng H-T, Gabutan E, Pagaspas GJ, Khan N, Hoxie H, 372 Hanna S, Holmes K, Gao N, Lewis R, Wang H, Neumann D, Chan A, Takizawa M, 373 Lowe J, Chen X, Kelly B, Asif A, Barnes K, Khan N, May B, Chowdhury T, Pollonini 374 G, Gouda N, Guy C, Gordon C, Ayoluwa N, Colon E, Miller-Medzon N, Jones S, 375 Hossain R, Dodson A, Weng M, McGaskey M, Vasileva A, Lincoln AE, Sikka R, 376 Wyllie AL, Berke EM, Libien J, Pincus M, Premsrirut PK. 2021. Implementation of a 377 pooled surveillance testing program for asymptomatic SARS-CoV-2 infections in K-378 12 schools and universities. EClinicalMedicine 38:101028.
- 379 16. Vander Schaaf NA, Fund AJ, Munnich BV, Zastrow AL, Fund EE, Senti TL, Lynn
 380 AF, Kane JJ, Love JL, Long GJ, Troendle NJ, Sharda DR. 2021. Routine, Cost381 Effective SARS-CoV-2 Surveillance Testing Using Pooled Saliva Limits Viral
 382 Spread on a Residential College Campus. Microbiol Spectr 9:e0108921.

383 17. Fenichel EP, Tobias Koch R, Gilbert A, Gonsalves G, Wyllie AL. 2021. 384 Understanding the Barriers to Pooled SARS-CoV-2 Testing in the United States. 385 Microbiology Spectrum 9. 386 Allicock OM, Yolda-Carr D, Earnest R, Breban M, Vega N, Ott IM, Kalinich C, Alpert 18. 387 T, Petrone M, Wyllie AL. 2021. Method versatility in RNA extraction-free PCR of 388 detection SARS-CoV-2 in saliva samples. medRxiv 389 doi:10.1101/2021.12.27.21268334.

390





